This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Lexicon Pharmaceuticals, Inc. (LXRX)
Morgan Stanley Healthcare Conference Call
September 11, 2012, 08:00 am ET
Arthur Sands - President & CEO
Brian Zambrowicz - EVP & Chief Scientific Officer
David Friedman - Morgan Stanley
PresentationDavid Friedman - Morgan Stanley
Okay. Thanks everyone for joining us here today. I am David Friedman one of the biotech analysts. Up here we have the team from Lexicon; on the far side, Brian Zambrowicz, Executive Vice President and Chief Scientific Officer and then on the near side here Arthur Sands, President and CEO.
So thank you very much both of you for coming and we would love this to be as interactive as possible, so everyone please feel free to ask any questions; you can just raise your hand and we’ll get you a microphone.
So thank you all for coming. You guys have a lot going on as usual. So, may be if you want to give a couple of minute overview of the company for those who aren’t familiar and your unique approach to drug development.
Yeah, so we have five compounds in drug development, all derived from our genomic platform which I think is unique to Lexicon. That platform we developed and evolved over the last 15 years based on gene knockout technology, so all of the targets were identified starting with the human genome, but then again what’s unique and I think advantageous about our drug discovery system is that we model each of these targets in knockout before we embark on a drug discovery program.